Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

H. Jones, Robert; Casbard, Angela; Carucci, Margherita; Cox, Catrin; Butler, Rachel; Alchami, Fouad; Madden, Tracie‐Ann; Bale, C.; Bezecny, Pavel; Joffe, Johnathan; Moon, Sarah; Twelves, Chris; Venkitaraman, Ramachandran; Waters, Simon; Foxley, Andrew; J. Howell, Sacha

doi:10.1016/s1470-2045(19)30817-4

Public

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Published in The Lancet Oncology • Feb 5, 2020

Authors:

Robert H. Jones

Angela Casbard

Margherita Carucci

Abstract

BACKGROUND: Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of the serine/threonine kinase AKT. The FAKTION trial investigated whether the addition of capivasertib to fulvestrant improved progression-free survival in patients with aromatase inhibitor-resistant advan...

Subject

Fulvestrant

Medicine

Aromatase inhibitor

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!